Allogeneic hematopoietic cell transplantation in acute myeloid leukemia

• Published in: Best practice & research. Clinical haematology 2023-06, Vol.36 (2), p.101466-101466, Article 101466
• Main Authors: Magee, Gray, Ragon, Brittany Knick
• Format: Article
• Language: English
• Subjects: Acute myeloid leukemia; Stem cell transplantation
• ISSN: 1521-6926; 1532-1924
• DOI: 10.1016/j.beha.2023.101466

Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment modality for select patients with acute myeloid leukemia (AML), functioning as a restorative agent following intensified chemo- and/or radiotherapy and also engendering the disease-directed immunologic threat of graft-versus-leukemia effect. Advancements in conditioning regimen intensity, donor availability, and supportive care have broadened the eligibility for allogeneic HCT, reduced rates of transplant related mortality, and improved outcomes over time. There are still obstacles to transplant in AML, offering opportunities for ongoing discovery, including poor recipient fitness, insufficient donor availability for certain populations, and limited access to care. Relapse remains the most common cause of treatment failure and a high priority area of investigative efforts. Post-transplant maintenance and novel applications of cellular therapeutics are expected to usher in a new era of promise for successful HCT in AML and will aim to overcome the remaining barriers impeding favorable outcomes for these patients.